Abbvie Inc.

Abbott Laboratories Corporation

Enanta Pharmaceuticals, Inc.

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Jianzhang Mei

David R Hill

Michael J Abrahamson

Kirill A Lukin

Timothy B Towne

Kenneth M Engstrom

Russell Drew Cink

Marvin Robert Leanna

Dennie S Welch

Gang Zhao

Richard D Bishop

Westin H Morrill

Matthew M Ravn

Jeff M Kallemeyn

Matthew J Pelc

Rodger F Henry

Jason S Tedrow

Sean M Mellican

Cathie L Linton

Nahathai Charukamnoetkanok

Yat Sun Or

Dale J Kempf

Anthony Ralph Haight

Ying Sun

Yonghua Gai

Keith F McDaniel

Sanjay R Chemburkar

Ahmad Y Sheikh

David J Grampovnik

Hui-Ju J Chen

Shashank Shekhar

Jason P Shanley

Dong Liu

Thaddeus Stephan Franczyk, Ii

Seble H Wagaw

Rajarathnam E Reddy

Su Yu

Maureen Ann McLaughlin

Lei Wang

Angelica B Kielbus

Tim Grieme

Yiyin Ku

William T Riordan

Stefan Mix

Gareth J Brown

Sun Or Yat

Thaddeus S Ii Franczyk

Maureen Ann Mclauglin

Sable H Wagaw

Ken Engstrom

Hui-Ju Chen

Keith F Mcdaniel

The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.

Synthetic route to anti-viral agents

The invention provides methods of synthesizing compounds in an asymmetric or enantioenriched fashion, wherein the compounds are useful intermediates in the synthesis of viral protease inhibitors.

Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof

Disclosed are methods of synthesizing enantioenriched difluoroalkylcyclopropyl amino esters and their salts, such as the dicyclohexylamine salt of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropane carboxylic acid. These compounds are useful intermediates in the synthesis of viral protease inhibitors.

Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Macrocyclic hepatitis C serine protease inhibitors

Processes to make compounds, including N-acylsulfonamide apoptosis promoters are disclosed.

Processes to make apoptosis promoters

A crystalline N-(4-(4-aminothieno[2,3 -d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate characterized in the monoclinic crystal system and P2/n space group, when measured with radiation at 0.7107 &#x212b;, by lattice parameters a, b and c of 5.0318 &#x212b;&#xb1;0.006 &#x212b;, 23.684 &#x212b;&#xb1;0.002 &#x212b; and 18.877 &#x212b;&#xb1;0.002 &#x212b;, respectively, and &#x3b2; of 90.703&#xb1;0.003, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.

Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate

A crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate characterized in the triclinic crystal system and P-1 space group, when measured with radiation at 0.7107 &#x212b;, by lattice parameters a, b and c of 7.800 &#x212b;&#xb1;0.001 &#x212b;, 13.406 &#x212b;&#xb1;0.002 &#x212b; and 13.554 &#x212b;&#xb1;0.002 &#x212b;, respectively and &#x3b1;, &#x3b2; and &#x3b3; of 67.155&#xb1;0.002, 79.724&#xb0;&#xb1;0.002&#xb0; and 84.067&#xb1;0.002, respectively, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.

Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate

Growing community of inventors

Lake Forest, IL, United States of America

Jianzhang Mei